CN108414479A - A kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents - Google Patents
A kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents Download PDFInfo
- Publication number
- CN108414479A CN108414479A CN201810055615.2A CN201810055615A CN108414479A CN 108414479 A CN108414479 A CN 108414479A CN 201810055615 A CN201810055615 A CN 201810055615A CN 108414479 A CN108414479 A CN 108414479A
- Authority
- CN
- China
- Prior art keywords
- iga
- distribution
- nephrosis
- purposes according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention provides a kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents, and the immune composition includes anti-IgA antibody, and the IgA nephrosis Non-invasive detection is included in acquisition and detects Immunoglobulin IgA from the biological sample of subject.Immune composition provided by the invention is used to prepare IgA nephrosis Non-invasive detection reagents, which can obtain the testing result highly consistent with biopsy, has higher detection accuracy to IgA nephrosis；And the detection method is non-invasive, and a kind of quick and noninvasive detection method is provided for the antidiastole of IgA nephrosis.
Description
Technical field
The present invention relates to the detections of IgA nephrosis, and in particular to a kind of immune composition is used preparing IgA nephrosis Non-invasive detections
Purposes in reagent.
Background technology
IgA nephrosis is a kind of most commonly seen primary glomerulopathy, refers to that glomerular mesangium area is heavy with IgA or IgA
Based on product, companion or the primary glomerular disease deposited in glomerular mesangium area without other immunoglobulins.Lesion type packet
Include focal segmental lesion, in capillary proliferative lesion, mesangial matrix * venereal disease become, crescent lesion and sclerotic conditions
Deng.Its clinical manifestation is repeated relapsing gross hematuria or microscopic hematuria, can be with different degrees of albuminuria, and some patientss can be with
There is severe hypertension or renal insufficiency.
IgA nephrosis is divided into Primary IgA nephropathy and secondary IgA nephrosis two types.Wherein, Primary IgA nephropathy by
Kidney disease itself causes.Secondary IgA nephrosis is caused by the disease other than kidney, such as purpura nephritis, HIV infection, serum
Negative joint of vertebral column inflammation, tumour, leprosy, liver diseases, familial IgA nephrosis etc..
Current clinically used IgA nephrosis detect and diagnose method is biopsy, i.e. renal fibroblast inspection.However, kidney is worn
It is a more complicated, higher inspection method of technology content that thorn, which checks, is generally required in three-level to go to the hospital and its related
Testing agency's cooperation carries out, and popularization is poor.In addition, renal fibroblast is a kind of invasive detection means, subject needs to be hospitalized
Night is difficult to completing to check as clear curative effect during chronic disease therapy and the multiplicating inspection needed for prognosis
Means.Moreover, renal fibroblast also has the risk for causing internal haemorrhage.
Drawbacks described above based on the prior art, it is a kind of for the efficient, simple, non-intruding of IgA nephrosis there is an urgent need for developing
Detect and diagnose method and reagent for this method.
Invention content
The inventors discovered that IgA nephrotic's urines centrifuge the Immunoglobulin IgA of sediment separation and/or contain IgA's
Immune complex tests positive, and the two presence and distribution situation it is related to the severity of IgA nephrosis.The present inventor
A kind of non-invasive detection methods of IgA nephrosis and the reagent for the non-invasive detection methods are invented accordingly, to overcome existing inspection
The deficiency and limitation of survey method.
According to the present invention, a kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents is provided, it is described
Immune composition includes anti-IgA antibody, and the IgA nephrosis Non-invasive detection is included in acquisition and is examined from the biological sample of subject
Survey Immunoglobulin IgA.
Wherein, the biological sample is the urine deposits by centrifugal treating, during the urine deposits include following
It is one or more：Cell, cell fragment and the immune complex being attached on cell or cell fragment.
Wherein, the IgA nephrosis Non-invasive detection is Immunofluorescence test.
The Immunofluorescence test follows the steps below：
(1) it is contacted from the biological sample of subject using the immune composition as primary antibody with the acquisition, forms antibody-
Antigenic compound, washing remove unbonded primary antibody；
(2) secondary antibody that fluorescent marker is added is dyed, and washing removes unbonded secondary antibody；
(3) film-making, the position using fluorescence microscope fluorescent label signal and distribution.
In above-mentioned steps (3), according to the position and distribution of the position of the fluorescent label signal and distribution assessment IgA.
Wherein, the distribution of the IgA includes graininess distribution, block distribution, strip distribution, Filamentous distribution and threadiness point
It is one or more in cloth.
Wherein, the distribution of the IgA indicates the severity of the IgA nephrosis.
Wherein, judge that the Lee of the IgA nephrosis is classified according to the distribution of the IgA, the Lee classifications include I-V grades.
The IgA nephrosis Non-invasive detection can also be that immunoblotting analysis detects.
The immune-blotting method is included in the acquisition and detects the presence of IgA from the biological sample of subject and its divide
Son amount.
Immune composition provided by the invention is used to prepare the Non-invasive detection reagent of IgA nephrosis, has following beneficial
Effect：
(1) non-invasive detection methods can obtain the testing result highly consistent with biopsy, to IgA nephrosis have compared with
High detection accuracy；
(2) non-invasive detection methods are non-invasive, avoid causing unnecessary damage to subject, and sample letter
Just, detection is quick and easy；
(3) present invention provides a kind of quick and noninvasive detection method for the antidiastole of IgA nephrosis, be Renal biospy it
Outer another detection and diagnostic mode, and provide detectable means at any time for the curative effect observation needed for chronic kidney disease long-term treatment；
(4) non-invasive detection methods provided by the invention can be as a kind of routine carrying out woundless testing to IgA nephrosis
Project receives renal needle biopsy for part refusal or has the patient of renal fibroblast contraindication to provide another option or conduct
Judge whether to need the Preliminary detection before renal needle biopsy, it also can be right unconditionally to carry out the medical institutions of renal needle biopsy
IgA nephrotics carry out timely diagnosing and treating and provide new method.
Description of the drawings
Fig. 1 is shown according to the separation of the sample to be tested of one embodiment of the present invention and detection method flow chart.
Fig. 2 shows the immunofluorescence test result according to the IgA nephrotics of one embodiment of the present invention, it illustrates
The Immunofluorescent signals of IgG4 and IgA.
Fig. 3 shows the IgA Immunofluorescence test images of normal healthy subjects.
Fig. 4 shows the IgA Immunofluorescence test images with different severity IgA nephrotics, wherein Fig. 4 A are shown
The IgA Immunofluorescence test images of II grades of IgA nephrotics are classified with Lee；Fig. 4 B show to be classified III level IgA kidneys with Lee
The IgA Immunofluorescence test images of patient；Fig. 4 C show the IgA immunofluorescences inspection that IV grades of IgA nephrotics are classified with Lee
Altimetric image.
Fig. 5 shows the Western Blot detection knots of IgA nephrotics, normal subjects and membranous nephropathy Urine in Patients
Fruit.
Specific implementation mode
Below by the drawings and specific embodiments, the present invention is described in more detail.Pass through these explanations, the present invention
The characteristics of and advantage will become more apparent from it is clear.
Term used in the context of the invention " positive " refers to the detection signal that can be detected.
It may refer to " in one embodiment " and " in another embodiment " used in the context of the invention
Identical embodiment can also refer to different embodiments.
The present invention provides a kind of detection side for IgA nephrosis biomarkers in subject's urine cell and cell fragment
Method and reagent for the detection method, testing result are similar to the inspection result of biopsy.The present invention is IgA nephrosis
Antidiastole and examine more afterwards and provide a kind of quick and noninvasive detection method, become the another detection except biopsy
With diagnostic mode, and for needed for chronic kidney disease long-term treatment curative effect observation detectable means at any time are provided.
According to the present invention, a kind of immune composition is provided, which includes anti-IgA antibody.
According to the present invention, the immune composition can be specifically bound with IgA, generate immune complex, thus into one
Step detects the presence and distribution of IgA by Immunofluorescence test or immune-blotting method.
In one embodiment, the immune composition is as the primary antibody in Immunofluorescence test.
According to the present invention, a kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents, institute are also provided
It includes anti-IgA antibody to state immune composition, and the IgA nephrosis Non-invasive detection is included in acquisition from the biological sample of subject
Detect Immunoglobulin IgA.
Wherein, the biological sample is the urine deposits by centrifugal treating, during the urine deposits include following
It is one or more：Cell, cell fragment and the immune complex being attached on cell or cell fragment.
In a kind of embodiment according to the present invention, the IgA nephrosis Non-invasive detection is Immunofluorescence test.
The Immunofluorescence test follows the steps below：
(1) it is contacted from the biological sample of subject using the immune composition as primary antibody with the acquisition, forms antibody-
Antigenic compound, washing remove unbonded primary antibody；
(2) secondary antibody that fluorescent marker is added is dyed, and washing removes unbonded secondary antibody；
(3) film-making, the position using fluorescence microscope fluorescent label signal and distribution.
In one embodiment, it in above-mentioned steps (3), is assessed according to the position of the fluorescent label signal and distribution
The position of IgA and distribution.
In one embodiment, the distribution of the IgA includes graininess distribution, block distribution, strip distribution, filiform point
It is one or more in cloth and threadiness distribution.
In one embodiment, the distribution of the IgA indicates the severity of the IgA nephrosis.
In one embodiment, judge that the Lee of the IgA nephrosis is classified according to the distribution of the IgA, the Lee points
Grade includes I-V grades.
In another embodiment according to the present invention, the IgA nephrosis Non-invasive detection can also be that immunoblotting analysis is examined
It surveys.The immune-blotting method is included in presence and its molecular weight that the acquisition detects IgA from the biological sample of subject.
In a kind of embodiment according to the present invention, the non-invasive detection methods of the IgA nephrosis include the following steps：
(1) it is detached to acquiring from the biological sample of subject, obtains sample to be tested；With
(2) Immunoglobulin IgA is detected in the sample to be tested.
The separation of sample to be tested
Acquisition of the present invention is preferably urine from the biological sample of subject, can pass through any side known in the art
Formula is acquired.
Subject of the present invention is mammal.In one embodiment, the subject is the mankind.In another kind
In embodiment, the subject is nephrotic.In another embodiment, the subject is doubtful with IgA kidneys
The human experimenter of disease.
The present invention provides a kind of method detached to cell in urine and cell fragment.This method is by being collected by centrifugation
Cell in urine and cell fragment, thus successfully by cell or the adhesion immune complex on cell fragment surface and generally
Dissolubility protein molecular is detached, and technical support is provided for subsequent detecting step.
This method can exclude to interfere sex chromosome mosaicism present in immune complex detection.This method has sample to be tested
Effect concentration also substantially increases the sensitivity of detection while removal soluble chaff interferent, and make to be difficult to detect originally low contains
Amount ingredient can detected easily.
In a kind of embodiment according to the present invention, the sediment that urine sample is obtained through centrifugal sedimentation carries out coverslip
Or glass slide smear, or carry out smear again after fixation, for detection, the detection includes but not limited to immunofluorescence
It is one or more in detection, immunochemistry detection, biochemistry detection.In one embodiment, the urine sample is 10-
40ml.In one embodiment, the urine sample preferably centrifuges 5-20 minutes by 1000-4000 revs/min of centrifugation,
More preferably centrifugation 10 minutes.
In one embodiment, centrifugal sedimentation can be substituted with the mode of multiple rejection tablet.
In one embodiment, the sediment passes through further centrifuge washing to remove the soluble egg in urine
In vain, then by the sediment after washing dissolving is resuspended for use in detection.
In one embodiment, the sediment is fixed by suspending, and preferably carries out suspension fixation with paraformaldehyde.
In a kind of embodiment, 30 minutes are fixed using the 4% paraformaldehyde suspension of 0.5ml.
In one embodiment, treated sample to be tested drop will be passed through on coverslip or glass slide, or
Sample to be tested is got rid of on the cover slip and dried with rejection tablet machine.
The sample to be tested include it is following in it is one or more：Cell, cell fragment and it is attached to cell or cell
Immune complex on fragment.
The detection of sample to be tested
In a kind of embodiment according to the present invention, Immunoglobulin IgA is detected in the sample to be tested.
In a kind of embodiment according to the present invention, the detection method further includes detecting to contain in the sample to be tested
There is the immune complex of IgA.
Immunoglobulin IgA and exempt from containing IgA in a kind of embodiment according to the present invention, in the sample to be tested
At least one of epidemic disease compound is positive in the detection.
In a kind of embodiment according to the present invention, Immunoglobulin IgA and the immune complex containing IgA it is common
In the presence of instruction, the subject suffers from IgA nephrosis.
In one embodiment, the presence of the Immunoglobulin IgA individually indicates that the subject suffers from IgA kidneys
Disease.
In one embodiment, the presence of the immune complex containing IgA individually indicates that the subject suffers from
IgA nephrosis.
In a kind of embodiment according to the present invention, the detection method further includes being assessed in the sample to be tested
The distribution of IgA.
In one embodiment, the distribution of the IgA indicates that the subject suffers from the severity of IgA nephrosis.
In one embodiment, the severity of the IgA nephrosis is divided into I-V grades according to Lee grade scales, classification
Feature is as follows：
I grade：Its glomerulus of the patient of this phase is most normal, slight mesentery broadening (segment) companion and (or) not companion once in a while
Hyperplasia, renal tubule and renal interstitial do not change then, this is a most light type in Lee classifications.
II grade：Patient's glomerulus of this phase show focal Parameters Associated with Mesenteric Proliferation and hardening (<50%), there are rare small crescent, kidney
Tubule and renal interstitial are harmless.This phase lesion for the first phase is heavier, is focal lesion under light microscopic, and lesion affects
The partial leaflet (segment) of a small number of glomerulus (focal) and glomerulus.
III grade：The glomerulus of patient is in the increment of diffusivity mesentery and broadening (focal segmental once in a while), accidental small crescent at this time
Body；Renal tubule and renal interstitial change then show focal renal interstitial oedema, accidental cellular infiltration, rare renal tubule atrophy.Carefully
Born of the same parents' infiltration can lead to inflammatory reaction, and at this time if prevented not in time, renal function is thin during inflammatory reaction
Phenotypic Change can occur for born of the same parents, and can release a series of cause nephritoxic factors.The area of glomerulosclerosis can increase, and renal tubule withers
Contracting can also increase, and there is also renal interstitial Renal vascular fibrosis.
IV grade：Glomerular lesions are in severe diffusivity mesangial matrix * and hardening, part or all of glomerulosclerosis, it is seen that new
Month body (<45%).Renal tubule atrophy, renal interstitial infiltration, accidental renal interstitial foam cells.By for crescent in this parting：This
Crescent is close to 50% in type, it may be said that patient is not if being noted that, it is likely that will reach this number, and study
Show when crescent is more than 50% or more of glomerulus sum, as patients with crescent nephritis (or crescent IgA nephrosis), it is state
Interior II types-immune complex patients with crescent nephritis most common in addition to lupus nephritis, its severity are self-evident.
V grade：The property of Glomerular lesions is serious similar to IV grade, but more, and glomerulus crescent is formed>45%；Renal tubule and
Renal interstitial lesion is similar to IV grade, but more serious.The lesion of this phase IgA nephrosis is most serious in IgA nephrosis, so treating
Come also most difficult, the measure of IgA treatment of kidney disease is no different with IV grade for the treatment of, is only needed tightened up therapeutic scheme, is perhaps being treated
Time on also can be relatively long.
In one embodiment, the distribution of the IgA includes graininess distribution, block distribution, strip distribution, filiform point
It is one or more in cloth and threadiness distribution.Wherein, the distribution density of IgA is bigger, and larger block is more, and IgA nephrosis is got over
Seriously.
In one embodiment, Immunofluorescence test, immunochemistry detection, biochemistry detection are carried out to the sample to be tested
In it is one or more.
The Immunofluorescence test passes through one or both of the immune complex to Immunoglobulin IgA, containing IgA
Immunofluorescence dyeing is carried out, to detect the presence and distribution of these substances.
In one embodiment, in the Immunofluorescence test of the sample to be tested, Immunoglobulin IgA with contain
The common location of the immune complex of IgA indicates that the subject suffers from IgA nephrosis.
In one embodiment, in the Immunofluorescence test of the sample to be tested, Immunoglobulin IgA and contain
The positive signal of at least one of the immune complex of IgA weaken or turn out cloudy instruction IgA nephrotic's diseases improved or
It is completely recovered.
In one embodiment, the non-invasive detection methods can with blood testing use in conjunction, for making up IgA kidneys
The deficiency of sick blood testing.In another embodiment, the non-invasive detection methods can also be exploited separately for IgA nephrosis
It diagnoses and examines more afterwards.In another embodiment, the non-invasive detection methods are also used as judging whether to need to carry out kidney
The Preliminary detection of aspiration biopsy.
Embodiment
Embodiment 1 detaches
As shown in Figure 1, detached to acquiring from the urine sample of subject, it is specific as follows：
The 40ml freshly voided urine samples for acquiring subject centrifuge 10 minutes through 1000-4000 revs/min, collect sediment
(containing cell and cell fragment).Sediment is resuspended with PBS, centrifuges 10 minutes, washes away through 1000-4000 revs/min again
Remaining soluble protein collects sediment.Sediment is resuspended with PBS and is distributed into three parts of samples to be tested I, II, III.
Wherein, sample to be tested I fixes 30 minutes with the suspension of 4% paraformaldehyde of 0.5ml, for immunohistochemistry, immune glimmering
Light.The observation property detection such as Electronic Speculum.Gel-runing buffer is added in sample to be tested II, is used for immune-blotting method (Western
Blot).Protease inhibitors is added in sample to be tested III, is placed in -80 DEG C of preservations, for detections such as protein science chips.
2 Immunofluorescence test of embodiment
Immunofluorescence test is carried out to sample to be tested, it is specific as follows：
Using anti-human IgA antibody, anti-human mesangial cell marker antibody, anti-human extracellular matrix antibody as primary antibody；
Antibody serum source is mouse, rabbit or sheep, monoclonal antibody or mostly anti-；
The anti-mouse of donkey, donkey anti-rabbit or the anti-goat-anti body of donkey of the fluorescent markers such as FITC, Cy3 and Cy5 are secondary antibody；
Detection mode is a kind of single dye (primary antibody), double dyes (two kinds of primary antibodies) or three dyes (three kinds of primary antibodies)；
One antiantibody of immunofluorescence uses the phosphate buffer (PBS) containing 1% bovine serum albumin(BSA) (BSA) to dilute 100-200
Times, be incubated antibody before first with containing 0.2%Triton and 1%BSA PBS (PBST) be incubated 15-30 minute, primary antibody overnight incubation or
2-3 hours；
Two antiantibody of immunofluorescence also dilutes 100- with the phosphate buffer (PBS) containing 1% bovine serum albumin(BSA) (BSA)
200 times, incubation time 1-2 hours；
Primary antibody and secondary antibody are washed 3 times, every time 10 minutes with PBS after being incubated；
After secondary antibody has been incubated and has been washed with PBS, it is washed with water primary and then is contaminated 5 minutes with DAPI, mounting after washing 3 times；
Directly coupling, which can be used, in primary antibody has the corresponding antibodies of fluorescein or enzyme to carry out direct immuno-fluorescent antibody assay.
Detection image is referring to Fig. 2 and Fig. 3.
Fig. 2 is the Immunofluorescence test image of IgA nephrotics, as shown, the IgA positive signals of IgA nephrotics
Be in granular form or small crumby fragment, these chip distributions are on respective cells, cell fragment and fibrous material more.
Fig. 3 is the Immunofluorescence test image of normal healthy subjects, as shown, normal human urine sediment IgA letters
Number for feminine gender.
The urine IgA Immunofluorescence tests of 3 different degrees of IgA nephrotics of embodiment
According to present invention non-invasive detection methods described above, II, III, IV grades of IgA nephrosis are classified from Lee to acquisition and are suffered from
The urine of person carries out IgG4 Immunofluorescence tests respectively, and detection image is shown in Fig. 4.
Fig. 4 A are the Immunofluorescence test image that II grades of IgA nephrotics are classified with Lee, as shown, IgA signals are
Graininess not of uniform size, it can also be seen that fibrous structure.
Fig. 4 B are the Immunofluorescence test image that III level IgA nephrotics are classified with Lee, as shown, IgA signals
For graininess, it is seen that more fibrous structure and stiff bar.
Fig. 4 C are the Immunofluorescence test image that IV grades of IgA nephrotics are classified with Lee, as shown, IgA signals are more
For larger block and stiff strip or filiform.
4 immune-blotting method of embodiment
To acquisition from IgA nephrotics (4, wherein II grades of IgA nephrotic 1, III level IgA nephrotics 2, IV
Grade IgA nephrotics 1), the urine progress Western Blot inspections of normal subjects (1) and membranous nephropathy patient (2)
It surveys, as a result sees Fig. 5.
As shown in figure 5, normal subjects and membranous nephropathy Urine in Patients sample the IgA signals in Western Blot detections
For feminine gender；II grades and III level IgA nephrotics urine sample IgA in Immunofluorescence test and Western blot detections are believed
Number it is the positive；But IV grades of IgA nephrotics urine samples are the positive in Immunofluorescence test IgA signals, and in Western
IgA signals are feminine gender in blot detections, this may be this knot caused by IgA on block and stiff filiform can not dissolve
Fruit is likely to become another index of IgA nephrosis deciding grade and level.
A kind of example of the present invention has shown and described in above description, but as previously described, it should be understood that the present invention is not office
Be limited to form disclosed herein, be not to be taken as excluding other embodiments, and can be used for various other combinations, modification and
Environment, and can be changed by the above teachings or related fields of technology or knowledge in the scope of the invention is set forth herein
It is dynamic.And changes and modifications made by those skilled in the art do not depart from the spirit and scope of the present invention, then it all should be appended by the present invention
Add in scope of the claims.
It is described the invention in detail above in association with preferred embodiment and exemplary example.But needs are stated
It is that these specific implementation modes are only the illustrative explanations to the present invention, do not constitute any limit to protection scope of the present invention
System.Without departing from spirit of that invention and protection domain, the technology of the present invention content and embodiments thereof can be carried out
Various improvement, equivalencing or modification, these each fall in protection scope of the present invention.Protection scope of the present invention is with appended power
Subject to profit requires.
Claims (10)
1. a kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents, the immune composition includes anti-
IgA antibody, the IgA nephrosis Non-invasive detection are included in acquisition and detect Immunoglobulin IgA from the biological sample of subject.
2. purposes according to claim 1, which is characterized in that the biological sample is the urine precipitation by centrifugal treating
Object, the urine deposits include it is following in it is one or more：Cell, cell fragment and it is attached to cell or cell is broken
The immune complex of on piece.
3. purposes according to claim 1, which is characterized in that the IgA nephrosis Non-invasive detection is Immunofluorescence test.
4. purposes according to claim 3, which is characterized in that the Immunofluorescence test follows the steps below：
(1) it is contacted from the biological sample of subject using the immune composition as primary antibody with the acquisition, forms antibody-antigene
Compound, washing remove unbonded primary antibody；
(2) secondary antibody that fluorescent marker is added is dyed, and washing removes unbonded secondary antibody；
(3) film-making, the position using fluorescence microscope fluorescent label signal and distribution.
5. purposes according to claim 4, which is characterized in that assessed according to the position of the fluorescent label signal and distribution
The position of IgA and distribution.
6. purposes according to claim 5, which is characterized in that the distribution of the IgA includes graininess distribution, bulk point
It is one or more in cloth, strip distribution, Filamentous distribution and threadiness distribution.
7. purposes according to claim 6, which is characterized in that the distribution of the IgA indicates the serious journey of the IgA nephrosis
Degree.
8. purposes according to claim 6, which is characterized in that judge the IgA nephrosis according to the distribution of the IgA
Lee is classified, and the Lee classifications include I-V grades.
9. purposes according to claim 1, which is characterized in that the IgA nephrosis Non-invasive detection detects for immunoblotting analysis.
10. purposes according to claim 9, which is characterized in that the immune-blotting method be included in it is described acquisition from by
Presence and its molecular weight of IgA are detected in the biological sample of examination person.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810055615.2A CN108414479A (en) | 2018-01-19 | 2018-01-19 | A kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810055615.2A CN108414479A (en) | 2018-01-19 | 2018-01-19 | A kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108414479A true CN108414479A (en) | 2018-08-17 |
Family
ID=63125855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810055615.2A Pending CN108414479A (en) | 2018-01-19 | 2018-01-19 | A kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108414479A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287503A (en) * | 2005-08-03 | 2008-10-15 | Rq生物科技有限公司 | Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases |
| CN101512339A (en) * | 2006-09-08 | 2009-08-19 | 日东纺绩株式会社 | Method for determination of antigen and antibody against the antigen, and determination reagent for use in the method |
| CN102047115A (en) * | 2008-06-02 | 2011-05-04 | 卫材R&D管理有限公司 | Iga nephropathy detection method and detection kit |
| CN105181973A (en) * | 2015-09-10 | 2015-12-23 | 付冬霞 | Diabetes and nephropathy early detection marker composition, kit and using method thereof |
| US9750808B2 (en) * | 2002-08-16 | 2017-09-05 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-alpha associated disorders |
-
2018
- 2018-01-19 CN CN201810055615.2A patent/CN108414479A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9750808B2 (en) * | 2002-08-16 | 2017-09-05 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-alpha associated disorders |
| CN101287503A (en) * | 2005-08-03 | 2008-10-15 | Rq生物科技有限公司 | Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases |
| CN101512339A (en) * | 2006-09-08 | 2009-08-19 | 日东纺绩株式会社 | Method for determination of antigen and antibody against the antigen, and determination reagent for use in the method |
| CN102047115A (en) * | 2008-06-02 | 2011-05-04 | 卫材R&D管理有限公司 | Iga nephropathy detection method and detection kit |
| CN105181973A (en) * | 2015-09-10 | 2015-12-23 | 付冬霞 | Diabetes and nephropathy early detection marker composition, kit and using method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王茜 等: "IgA肾病", 《中国社区医师》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2592386B2 (en) | Method for detecting rupture of fetal membrane and test kit using the method | |
| CN104198712A (en) | Galectin-3 immunoassay | |
| CN108445232B (en) | Application of the NF-L in the detection of neurolues cerebrospinal fluid | |
| CN111349683B (en) | Application of basophils of granulocyte group as allergic disease diagnosis marker | |
| US10107814B2 (en) | Diagnostic method | |
| CN108414478A (en) | A kind of detection method of biological sample | |
| CN108426997A (en) | A kind of detection method of biological sample | |
| US11054426B2 (en) | Diagnostic method | |
| CN108414741A (en) | A kind of purposes of immune composition in preparing membranous nephropathy Non-invasive detection reagent | |
| CN108463724A (en) | The judgment method of cancer, the judgement device of cancer and computer program | |
| CN108414479A (en) | A kind of purposes of immune composition in preparing IgA nephrosis Non-invasive detection reagents | |
| CN116679046A (en) | Application of antibody in preparation of reagent for detecting membranous nephropathy and kit | |
| CN103995116B (en) | For the test strips and preparation method thereof of specificity cephalosporins anaphylactogen IgE examination | |
| CN113358874A (en) | Detection method for systemic lupus erythematosus autoantibodies | |
| JP2010151677A (en) | Uterine cancer diagnosis method and uterine cancer diagnosis kit | |
| CN109061174A (en) | The biomarker of systemic sclerosis diagnosis | |
| CN108761067A (en) | The biomarker and application thereof of idiopathic inflammatory myopathies detection | |
| EP3467497B1 (en) | Method for analyzing expression of smn protein nuclear body | |
| CN109294973A (en) | A method of blood urine enriched for leukemic cells epithelial cell is removed based on paramagnetic particle method feminine gender | |
| WO2017061152A1 (en) | Cervical cancer testing method and test reagent used therefor | |
| US20240053361A1 (en) | Use of alarmins as biomarkers for assessing ischemia-reperfusion injury severity after solid organ transplantation | |
| RU2334234C1 (en) | Method of oncological disease diagnostics and monitoring | |
| WO2017062946A1 (en) | LATERAL FLOW IMMUNOASSAY DEVICES, SYSTEMS AND METHODS FOR DETECTING α-THALASSEMIA 1 TRAIT SOUTHEAST ASIAN (SEA) TYPE | |
| CN108776215A (en) | Systemic sclerosis diagnoses and the biomarker of PAH predictions | |
| Duna et al. | Testing antinuclear antibodies in relatives of patients with systemic lupus erithematosus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180817 |